[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100531409":3},{"organization":4,"armGroups":7,"interventions":15,"overallOfficials":26,"centralContacts":31,"locations":40,"responsibleParty":55,"collaborators":21,"id":57,"slug":58,"hasResults":59,"nctId":60,"briefTitle":61,"officialTitle":62,"acronym":21,"eligibilityCriteria":63,"healthyVolunteers":59,"sex":64,"minAge":65,"maxAge":66,"enrollmentInfo":67,"targetDuration":21,"studyType":70,"phases":71,"briefSummary":73,"conditions":74,"keywords":21,"overallStatus":43,"whyStopped":21,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":85},{"fullName":5,"class":6},"Federal Research Institute of Pediatric Hematology, Oncology and Immunology","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"intervention\u002Ftreatment","EXPERIMENTAL","Conditioning regimen containing treosulfan 30-42 g\u002Fm2, fludarabine 150 mg\u002Fmg, thymoglobulin 5 mg\u002Fkg and thiotepa 10 mg\u002Fkg or melphalan 140 mg\u002Fm2\n\nGVHD prophylaxis regimen for matched unrelated (MUD) and matched related donors (MRD):\n\nCyclophosphamide (PTCY) 25 mg\u002Fkg\u002Fday (days +3, +4) Ruxolitinib 7 mg\u002Fm2 from day +5\n\nGVHD prophylaxis regimen for mismatched related donor (MMRD):\n\nCyclophosphamide (PTCY) 50 mg\u002Fkg\u002Fday (days +3, +4) Ruxolitinib 7 mg\u002Fm2 from day +5",[13,14],"Drug: Cyclophosphamide","Drug: Ruxolitinib",[16,22],{"type":17,"name":18,"description":19,"armGroupLabels":20,"otherNames":21},"DRUG","Cyclophosphamide","Cyclophosphamide 25mg\u002Fkg (days +3, +4) after HSCT from MUD and MRD Cyclophosphamide 50mg\u002Fkg (days +3, +4) after HSCT from MMRD",[9],null,{"type":17,"name":23,"description":24,"armGroupLabels":25,"otherNames":21},"Ruxolitinib","Ruxolitinib 7 mg\u002Fm2 from day +5 after HSCT",[9],[27],{"name":28,"affiliation":29,"role":30},"Dmitry Balashov, MD, PhD","National Research Center for Pediatric Hematology, Moscow, Russia","STUDY_CHAIR",[32,36],{"name":28,"role":33,"phone":34,"phoneExt":21,"email":35},"CONTACT","+74956647091","bala8@yandex.ru",{"name":37,"role":33,"phone":38,"phoneExt":21,"email":39},"Alexandra Laberko, MD, PhD","74952876570","alexandra.laberko@gmail.com",[41],{"facility":42,"status":43,"city":44,"state":21,"zip":21,"country":45,"countryCode":46,"cosmosGeoPoint":47,"geoPoint":52,"contacts":53},"HSCT department","RECRUITING","Moscow","Russia","RU",{"type":48,"coordinates":49},"Point",[50,51],37.61781,55.75204,{"lat":51,"lon":50},[54],{"name":28,"role":33,"phone":34,"phoneExt":21,"email":35},{"type":56,"investigatorFullName":21,"investigatorTitle":21,"investigatorAffiliation":21,"oldNameTitle":21,"oldOrganization":21},"SPONSOR","100531409","phase-2-ptcy-and-and-ruxolitinib-for-gvhd-prophylaxis-after-hsct-with-thymoglobulin-in-conditioning-regimen-in-patients-with-inborn-errors-of-immunity-100531409",false,"NCT06199427","PTCy and and Ruxolitinib for GVHD Prophylaxis After HSCT With Thymoglobulin in Conditioning Regimen in Patients With Inborn Errors of Immunity","Safety and Efficacy of Cyclophosphamide and Ruxolitinib for Graft-versus-host-disease Prophylaxis After Hematopoietic Stem Cell Transplantation With Thymoglobulin Serotherapy in Conditioning Regimen in Patients With Inborn Errors of Immunity","Inclusion Criteria:\n\n1. Patients aged ≥ 0 months and \\\u003C 21 years\n2. Patients diagnosed with NBS eligible for an allogeneic HSCT\n3. Signed written informed consent signed by a parent or legal guardian\n\nExclusion Criteria:\n\nConcomitant severe somatic disease associated with an additional risk of severe complications","ALL","0 Months","21 Years",{"count":68,"type":69},100,"ESTIMATED","INTERVENTIONAL",[72],"PHASE2","The aim of the current study is to evaluate the efficacy of combined regimen of GVHD prophylaxis with thymoglobulin in conditioning regimen and PTCY with ruxolitinib used after HSCT in patients with inborn errors of immunity (IEI)",[75],"Inborn Errors of Immunity","2023-12-28",{"date":78,"type":79},"2024-01-10","ACTUAL",{"date":81,"type":79},"2023-11-21",{"date":83,"type":69},"2027-12-31",{"name":5,"class":6},1]